D.E. Shaw & Co’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

D.E. Shaw & Co’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-25,580	Closed	-$1.23M	–	4397
2020 Q1	$1.23M	Buy	+25,580	New	+$1.19M	﹤0.01%	2580
2019 Q4	–	Sell	-157,655	Closed	-$6.97M	–	4271
2019 Q3	$3.73M	Sell	157,655 -259,215	-62%	-$7.68M	﹤0.01%	1871
2019 Q2	$12.5M	Sell	416,870 -121,976	-23%	-$2.79M	0.02%	1012
2019 Q1	$12.1M	Buy	538,846 +291,604	+118%	+$6.27M	0.02%	990
2018 Q4	$4.5M	Buy	247,242 +141,395	+134%	+$2.22M	0.01%	1580
2018 Q3	$1.92M	Buy	105,847 +84,227	+390%	+$998K	﹤0.01%	2226
2018 Q2	$215K	Buy	+21,620	New	+$149K	﹤0.01%	3530
2017 Q4	–	Sell	-28,563	Closed	-$417K	–	3827
2017 Q3	$417K	Buy	28,563 +6,807	+31%	+$103K	﹤0.01%	3005
2017 Q2	$408K	Sell	21,756 -16,088	-43%	-$363K	﹤0.01%	2898
2017 Q1	$806K	Sell	37,844 -3,556	-9%	-$68K	﹤0.01%	2452
2016 Q4	$629K	Buy	+41,400	New	+$563K	﹤0.01%	2727

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

D.E. Shaw & Co's RARX Position: Q2 2020 in Review

D.E. Shaw & Co sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 25,580 shares — an estimated $1.23M sold.

D.E. Shaw & Co first reported a position in RARX in Q4 2016 and held it in 11 quarters. The position peaked at $12.5M in Q2 2019. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

D.E. Shaw & Co reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
D.E. Shaw & Co sold 25,580 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $1.23M.
D.E. Shaw & Co first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2016 and held it in 11 quarters.
D.E. Shaw & Co's Ra Pharmaceuticals, Inc. Common Stock position peaked at $12.5M in Q2 2019.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on D.E. Shaw & Co's 13F filing for Q2 2020, filed 14 Aug 2020.